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Reminiscence of 40-year research on nitrogen metabolism
By Akira ICHIHARA*1,†
(Communicated by Tasuku HONJO, M.J.A.)
Abstract: This article summarizes my research over 40 years. The main theme of my work is
nitrogen metabolism of amino acids, though later I focused on protein turnover in the cell. In the
ﬁrst years of my research work, I was busy dissecting the pathways involved in the metabolism of
certain amino acids and their related enzymes. Then I became interested in the physiology and
regulation of matabolism of these amino acids. For that, I used primary cultured hepatocytes, which
contain many liver-speciﬁc enzymes. However, this play ﬁeld was very rough around 1970 and hence
I had to smooth them (diﬀerentiated) ﬁrst. We discovered a speciﬁc growth factor (hepatocyte
growth factor, HGF) in rat platelets. Exceptionally, I also worked on branched chain amino acids
(valine, leucine and isoleucine). These amino acids are not eﬃciently metabolized in the liver, so I
had to consider the physiology of extrahepatic tissues as well. Finally, I came across a huge protease
complex, the proteasome. Whether these players, small amino acid metabolizing enzymes and the
huge protease complex, danced well in harmony on my playground or not, I still do not know.
Keywords: amino acids, metabolism, hepatocytes, HGF (hepatocyte growth factor),
proteasome, BCAA (branched chain amino acids)
I graduated from Osaka University Medical
School in 1952 and enrolled in the Graduate School
to work with Dr. Masami Suda in the Institute
of Microbial Diseases. Dr. Suda was an Assistant
Professor though there was no vacant Professor
position in the laboratory. He was young and active
in his research on protein turnover, particularly
substrate-induced enzyme induction. Historically,
biochemical research in the Medical School was
started by Professor Yashiro Kotake in the beginning
of the 20th century. He was interested in the
metabolism of amino acids, particularly tryptophan
and found kynurenin as an intermediate. He also
discovered urocanase as the ﬁrst enzyme to metab-
olize histidine. His ﬁndings were appreciated world-
wide at that time and he was asked to contribute to a
chapter on amino acid metabolism in volumes 3 and 4
(published in 1934 and 1935, respectively) of the
Annual Review of Biochemistry. In those days,
research in biochemistry was not very well regarded
in Japan and none had been asked before to write
a review. Consequent to this interest, research on
nitrogen metabolism ﬂourished in the Medical
School. When I started my work, many were
conducting research on the so-called O-o r.-
elimination by bacterial enzymes. These were release
of the last part of amino acid carbons, producing
phenol, indole, or methyl mercaptan from tyrosine,
tryptophan and methionine, respectively. My ﬁrst
task was to purify the cysteine desulfhydrase of
bacteria. At that time, it was thought that cysteine
was metabolized to ammonia, hydrogen sulﬁde and
pyruvate by a single-step reaction. However, Dr.
Suda suspected the following single-step mechanism:
Cysteine ¼) Pyruvate þ NH3 þ H2S
He anticipated a two-step reaction through an
intermediate compound. Working with him, I used
to culture soil bacteria every day and prepare cell free
extracts, then measure the reaction products men-
tioned above to construct the kinetic curve. However,
the research conditions at that time were tough;
e.g., high-quality biochemical reagents, especially
isotopes, and cold centrifuges were not available
commercially. So you can imagine that when I read
the journals at that time, I envied the progress of
work in the USA. Even now, when I smell hydrogen
sulﬁde, I recall vividly and sentimentally the poor
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much in my research work in the ﬁrst two years, but
we always discussed eagerly though sometimes
meaninglessly our research and how to improve it.
At that time, there was already the concept of “one
gene–one enzyme theory”, but there was no molecular
evidence of gene. The most common tools used to
measure enzyme activity were the Warburg’s man-
ometer and colorimetric photometer. Furthermore,
proteins were usually puriﬁed with acetone or
ammonium sulfate and there was certainly no column
fractionation.
Then in 1954, I was lucky to be given the
opportunity to work in the USA. My second mentor,
Dr. Yoshiro Takeda, who was a research assistant
working in Dr. Suda’s laboratory, left Japan to work
in the USA two years earlier and while there he
helped me ﬁnd work at the University of California/
Berkeley, Medical School, Department of Physiolog-
ical Chemistry under the supervision of Professor
D.M. Greenberg. It was quite unique under such poor
research conditions in Japan that Dr. Suda always
encouraged us to publish our work in English and to
visit US laboratory, although he himself had never
been abroad. While all this is not unusual today, but
in the ﬁfties of the last century, it was really diﬃcult
to write papers in English and to go to the USA.
Therefore, I always consider Dr. Suda as a remark-
able teacher for young students and I am grateful for
his help and vision.
Doing research and living in the USA were
wonderful. In the laboratory where I worked, every-
thing was available to do research and the academic
environment was marvelous. There were many
distinguished scientists and we always had hot
scientiﬁc discussions. Professor Greenberg was inter-
ested in the so-called “active one carbon unit”, which
was produced via tetrahydrofolic acid-mediated
donors, mainly from serine or glycine. He suggested
that pyruvate could be converted to serine via
transamiantion. He also advised me to use animals
only in my research rather than bacteria. This was
his policy in the laboratory. Accordingly, I started to
use [14C] pyruvate to measure the formation of serine
in rat liver homogenate, but naturally the product
was always alanine. Therefore, I thought that I
should start from glucose as the original source of
carbon for serine production. Indeed, [14C] glucose
was incorporated into isolated serine. Next, I looked
for possible precursor from glycolytic pathway and
thought that it might be 3-phosphoglyceric acid (3-
PG). Dr. Greenberg suggested that I should visit
Professor Calvin in the Photosynthesis Laboratory.
Professor Calvin had many paper-chromatograms
that contained various intermediates from [14C] CO2
to carbohydrates. I felt that this was a real university
where I could obtain a lot of information from
the people surrounding me. I was able to obtain
numerous chromatography papers and extracted
[14C] 3-PG. In the next step, I incubated this extract
with rat liver homogenate. Then I found [14C] serine
as a product. It was midnight in August 1955 and I
remember dancing around with tremendous joy in
the laboratory. My discovery happened just at the
end of my ﬁrst year in the USA and I was in anxious
to get good results. Subsequently, I proposed that
this 3-PG could be oxidized to 3-P-hydroxy pyruvate
(3-P-OHpyr) followed by transamination to form
phosphoserine (P-serine). This could be converted to
serine by a phosphatase (see the pathway below).
Glucose 3-PG P-Enol pyruvate Pyruvate
Serine P-Serine 3-p-OHpyr
Delighted and happy, I worked during the second
year to determine the dehydrogenase, transaminase
and phosphatase activities in the partially puriﬁed
liver extracts.1) The methods I used were mostly
paper chromatographies and colorimetry. The results
clearly showed that serine could be formed from 3-
PG, which is an intermediate of glycolysis. At that
time, everyone was getting excited about phospho-
rylation of proteins in biological specimens since none
had shown before the presence of free P-serine in
living material. It was also unique to ﬁnd phosphory-
lated intermediate in amino acid metabolism. My
work was accordingly appreciated in the ﬁeld of
metabolism research. Around the same time, Dr. H.
J. Sallach identiﬁed a non-phosphorylated pathway
through D-glycerate and subsequent research showed
that in fact both pathways were functional depending
on animal species and bacteria.2) Dr. Greenberg
published a series of monograph reviews on the
“Metabolic Pathways”, and my work was cited in
many papers.2)
In my third year (1956) in the USA, I moved to
the McCollum-Pratt Institute at Johns Hopkins
University in Baltimore, because I thought that I
should gain new experience. Research in this institute
was very active at that time and the Director of the
Institute, Dr. W. McElroy, organized annually a
high-caliber international symposium, under the title
of ‘Phosphorylation’ or ‘Nitrogen Metabolism’. Dr.
A. ICHIHARA [Vol. 86, 708McElroy’s Institute provided more freedom and some
of the people who worked in that Institute later
became world authorities in their ﬁelds such as Drs.
N. Kaplan, S. Collowick, and F. Kenny. With regard
to scientiﬁc research, Dr. McElroy reported that
luciferase activated by ATP produced biolumines-
cence, like in ﬁreﬂy. He suggested that I work in this
ﬁeld, but I thought immaturely that the medical ﬁeld
does not use bioluminescence and instead I decided to
focus on detoxiﬁcation of hydrogen sulﬁde to produce
thiosulfate (H2S2O3) in animals. This decision was
based on my nostalgic idea on sulfur metabolism,
which I used to work with. In animal, thiosulfate is
excreted following inhalation of hydrogen sulﬁde.
However, this work did not progress much within one
year and I found many non-enzymatic reactions
around hydrogen sulﬁde.
In September 1957, I returned to Osaka and was
appointed a Research Assistant at the Department of
Nutrition, School of Medicine, with Dr. Suda, who
had been at that time promoted to a Professor.
Again, I was lucky for being able to secure a position
as soon as I returned to Japan. I say this because I
know of the suﬀering of young graduates nowadays
in ﬁnding new posts. After coming back to Japan,
the Japanese Society of Biochemistry organized the
International Symposium of Enzyme Chemistry in
Tokyo and Kyoto, which represented the ﬁrst
international meeting of biochemistry in Japan. The
symposium was attended by several famous scientists
from around the world, who delivered excellent
lectures followed by heated discussion and resulted
in the publication of excellent papers.3) The sympo-
sium program also included several satellite meetings
including amino acid metabolism (Photo. 1). Inter-
estingly, the symposium provided the chance for
young Japanese biochemists to obtain work abroad.
Dr. Suda suggested that I start my work on
bacterial metabolism involving lysine oxidation,
including the production of 5-amino valeric acid,
ammonia and CO2 in a single-step reaction, which
was also anticipated to include an oxygenase enzyme.
Accordingly, I puriﬁed the enzyme and collaborated
with Professor Osamu Hayaishi, who was appointed
as Professor of Biochemistry at Kyoto University
Medical School at that time, and we showed that this
enzyme was probably an oxygenase whose function
was to oxidize lysine. Professor Hayaishi was an
expert in oxygenation and employed [18O] gas in his
experiments. Indeed, our work showed the incorpo-
ration of this molecular oxygen to produce 5-amino-
valeric acid. Later, his group showed that such lysine
oxygenation was a two-step reaction and involved
the production of 5-aminovaleramide.4),5) (see the
reaction pathway below)
In 1959, I was appointed Assistant Professor of
Biochemistry, Dental School of Osaka University.
This School had been established newly and chaired
by Professor Yoshiro Takeda, who was my second
mentor and since then we were very close friends.
Later, we both moved to Tokushima independently,
where I was appointed a Professor at the Medical
School while he became the ﬁrst Dean of the Dental
School. Both of us worked in the medical ﬁeld in the
past and had no experience in the dental ﬁeld. There
was very little biochemical work in the dental ﬁeld at
that time in Japan. Professor Takeda found a report
describing the isolation of liver cells by mechanical
dispersion of perfused liver. Accordingly, we used
this method to study metabolic regulation in the rat
liver. At that time, we became more interested in
metabolic regulation such as hormonal control of
gene expression than enzyme characterization,
although molecular biology was still not popular at
that time. Microscopic examination of the isolated
cells showed the beautiful round cells, but we later
found that these isolated cells were actually cells
damaged by mechanical dispersion and almost all
soluble enzymes leaked out from the cells during this
process, and therefore we were not able to show any
metabolic activity in that preparation. Of course,
that included no response to any of the hormones
tested in these damaged cells. This waste of time
and eﬀort was entirely due to our ignorance of the
intricate ﬁeld of cell culture and cell biology. We
struggled for several years to revive these dead cells
to no avail. Based on my experience and research
failure in the isolated liver cells, I learnt a lot about
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useful for speciﬁc work, they resemble cancer cells in
that they do not show normal metabolic activity and
also we wanted more diﬀerentiated cultured cells.
In 1965, I was appointed a Professor of Enzyme
Pathology at the Institute of Enzyme Research,
Tokushima University Medical School. Among the
several projects available to study, I chose the
characterization of transamination of branched chain
amino acids (BCAA, i.e., valine, leucine and iso-
leucine). Whether the transaminase was speciﬁc for
the three amino acids or each amino acid had a
speciﬁc transaminase was unknown at that time. I
found that the enzyme was fairly speciﬁc for BCAA,
although methionine was a substrate with low
activity.6) It was interesting that around the same
time, Dr. W.T. Jenkins in the USA reported similar
ﬁndings. His enzyme was more highly puriﬁed than
mine, but I showed a unique tissue distribution of this
enzyme in rats.7) Usually the liver shows high levels
of amino acid metabolism due to its gluconeogenic
nature, however BCAA transaminase is extremely
low in the liver, compared with moderate activity in
the muscle and heart, although their products, keto
acids, are degraded in the liver. This unique tissue
distribution is interesting, and later I found the
highest activity in the pancreas and stomach8)
(Table 1). Although the reason for the high enzyme
activity in the stomach and pancreas remains as a
mystery, it could be a signal for digestive juice
secretion. I later identiﬁed two types of the enzyme
(isozymes), including their characterization immuno-
logically9) (see Table 1). I also found that the isozyme
pattern in the rat hepatoma cells was diﬀerent from
that in the normal liver. BCAA are unique physio-
logically compared with other amino acids. Although
they are essential in animal nutrition, they are not
metabolized in the liver, but do so mostly in the
extrahepatic tissues, perhaps in the muscle. Muscles
constitute about 50% of body weight, hence although
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Photo. 1. Photograph of participants at the International meeting on amino acid metabolism held in Osaka, 1957. 1. Y. Takeda (Osaka),
2. Y. Sakamoto (Osaka), 3. M. Suda (Osaka), 4–6. Taiwan participants, 7. H. Wada (Osaka), 8. S. Yoshimatsu (Nara), 9. A. Ichihara
(Osaka), 10. Y. Masai (Osaka), 11. O. Hayaishi (Bethesda), 12. J. Matsumoto (Osaka), 13. Z. Matsuoka (Osaka), 14. Y. Sera (Osaka),
15. Y. Kotake (Wakayama), 16. O. Wiss (Basel), 17. B. Magasanik (Boston), 18. W.E. Knox (Boston), 19. E. E. Snell (Berkeley), 20.
A. E. Braunstein (Moscow), 21. R. Hirohata (Ube), 22. S. Ueda (Osaka), 23. Y. Kotake (Wakayama), 24. K. Ichihara (Osaka), 25. S.
Otani, 26. C. Fromageot (Paris).
A. ICHIHARA [Vol. 86, 710the BCAA transaminase activity is not very high in
the muscle, the total metabolizing activity must be
the highest in body. BCAA also constitute a high
percentage of the body proteins in general. Leucine
is used at high proportions for energy production
among other amino acids as well. It is also a potent
stimulator of insulin secretion. Therefore, BCAA may
be used as an energy source in animals. Based on these
considerations, it is interesting that BCAA, partic-
ularly leucine, are eﬀective in activation of protein
synthesis and inhibition of protein degradation both
in vivo and in vitro.10) However, the mechanisms
responsible for the eﬀects of BCAA on protein
turnover remain poorly understood. Interestingly
Dr. K. Yonezawa’s group used cultured cells and
reported that leucine stimulates mammalian target of
rapamycin (mTOR) kinase, which is an upstream
regulator of the ribosomal S6 protein kinase 1 and 4E-
BP1 (eIF4E binding protein 1), and hence mRNA
translation.11) Several groups showed that BCAA
prevent liver cirrhosis by providing energy and
possible signals to stimulate protein synthesis includ-
ing production of albumin and hepatocyte growth
factor (HGF).12) Clinically, Dr. T.E. Fischer proposed
the importance of blood BCAA/tyrosine and BCAA/
phenylalanine ratios, particularly in patients with
acute liver encephalopathy,13) though I do not know
the exact eﬀects and mechanism of action. I con-
tributed to writing achapter on BCAA in the Reviews
of Enzymology and Physiology of BCAA.9),14) In
2004, I organized an International Symposium of the
Pathophysiology of BCAA in Tokyo.15)
On several occasions, our ﬁndings were similar to
those published by other scientists at almost the
same time independently. My report on serine
biosynthesis was published at the same time when
Dr. Sallach published his paper, as explained above.
What an incredible coincidence since we had no
contact previously. It makes me wonder how many
people have the same scientiﬁc interest in the same
ﬁeld at the same time who publish their ﬁndings at
the same time. The same also happened with regard
to the BCAA transaminase between my work and
that of Jenkins and his group.
In 1969, Berry and Friend reported the use of
collagenase to isolate rat hepatocytes that retain their
active liver-speciﬁc enzymes.16) I was really keen to
use this method in my studies designed to understand
liver metabolism. I have worked mostly with liver
speciﬁc enzymes, but it was the study of the enzymes
themselves and the understanding of their physiology
that interested me most rather than the regulation of
enzyme activity. I considered the method very useful
to study hormonal regulation of gene expression at
the living cell level. I cannot forget the joy I felt when
I found that the addition of glucocorticoid and
glucagon to the culture media of hepatocytes isolated
using the collagenase method truly induced serine
dehydratase and tryptophan dioxygenase, which are
liver-speciﬁc enzymes, whereas no such induction was
noted in mechanically dispersed cells or established
liver cells.17),18) We published many papers showing
that these primary cultured hepatocytes are really
mature liver cells and retain various diﬀerentiated
liver speciﬁc functions such as glyco-/gluconeo-
genesis, lipogenesis and the respective hormonal
responses.18) Among many markers of liver-speciﬁc
enzymes, we focused our attention on serine dehy-
dratase gene, because it is a central enzyme for the
conversion of amino acid carbons to glucose. This
gene was cloned and its molecular sequence was
determined.19) Furthermore, the genetic mechanisms
of the active responses of glucocorticoids and gluca-
gon were determined.20) These genetic techniques
quickly became popular at that time. In the early
period of my work, I was able to measure enzyme
activity only while hormonal regulations were studied
in hormone-treated animals and we called them gene
expressions. However, around the 1970s, we were able
to use the cell culture system for hormonal regulation
and gene manipulation studies.
Our main interest in hepatocyte research, how-
ever, was whether these cells could proliferate in vitro
in the presence of growth factor. It has been known for
Table 1. Tissue distribution of BCAA transaminase isozymes
Activity (unit)
Rat Human
Isozyme I (%)*
Liver 10 100 80
Lung 18 100
Kidney 139 100 90
Skeletal muscle 50 100 90
Brain 74 30 20
Heart 148 100 90
Stomach 820 100 90
Pancreas 1250 100 60
Ovary 50 70 50
Lactating mammary gland 100 100
*Rest of the percentage is type III.
BCAA isozymes are classiﬁed into types I, II, and III. Type I
and III are mainly localized in mitochondrial and cytosolic
fractions, respectively. Type II is currently assumed to be
identical to asparagine aminotransferase. In general, iso-
zyme III is increased in various transformed cells.
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could proliferate actively and recover the original
volume. We showed that there was indeed DNA
synthesis of primary cultured hepatocytes in the
presence of epidermal growth factor (EGF). Then we
searched for a growth factor speciﬁc for hepatocytes.
We checked for such factors in various rat tissues and
found that circulating platelets carry such factor. We
isolated platelets from over 5,000 rats and puriﬁed the
factor. Further analysis showed it was more than
80,000Da in size and consisted of a heterodimer. We
named it HGF. Around the same time, Dr. Toshikazu
Nakamura who was one of the most active researchers
in my laboratory was appointed as a Professor in
Science at Kyushu University. Later, he identiﬁed the
unique structure of HGF.21) He also found that HGF
was not only a liver growth factor, but also played
important roles in diverse cellular functions such as
angiogenesis, morphogenesis or anti-liver cirrhosis
activity. Dr. Nakamura then moved to Osaka Uni-
versity and is still currently in the same University,
where he reported that one domain of HGF (NK4),
which functions as a speciﬁc inhibitor of HGF, is a
potent anti-tumor drug.22) After he left Tokushima, I
became interested in the relation between hepatocyte
function and morphology of the cells in primary
cultures. It is common to use monolayer cultures to
examine the cell activities, but this is quite an artiﬁcial
setup and it should be more natural to mimic the in
vivo state. Several studies have described more natural
culture conditions such as coating dishes with extra-
cellular substratum, addition of various hormones or
nutrients.23) I found an interesting report using
positively charged culture dishes, in which cells
aggregate to become round and detach from dishes to
ﬂoat in the medium.24) The cultured spheroid-shaped
rat hepatocytes have similar morphological features
(Fig. 1). This technique yielded some remarkably
interesting results. Glucagon, insulin and glucocorti-
coids regulate the expression of liver-speciﬁce n z y m e s
in spheroid cultures more natural than in monolayer
cultures.Forexample,glucokinaseisupregulatedwhile
hexokinase is downregulated in spheroid cultures25)
(Fig. 2), as if hepatocytes are mature cells at resting
condition. Interestingly, the transfer of the spheroid
cultured cells to monolayer cultures resulted in the
gradual reversal of the expression; i.e., downregulation
of glucokinase and upregulation of hexokinase. The
latter pattern is similar to that seen in hepatoma cells.
Ofcourse, the culturedhepatocyteswerenot cancerous
cells in both the monolayer and spheroid cultures, but
they seem to transform into the Gl state of the cell
cycle from a resting state. In spheroid cultures, cells do
not proliferate even in the presence of HGF. It is
possible that the intracellular structure of the cells in
spheroid cultures would generate more natural signals
to regulate gene expressions, although this could not
have beenstudied sincegene structure analysiswas not
available. Thus, we considered that the intracellular
environment seems more important for signal trans-
duction to gene activation. However, my knowledge of
Fig. 1. Changes in the morphology of cultured rat hepatocytes in
monolayers (top) and spheroid cultures (bottom).
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Fig. 2. Activities of glucokinase and hexokinase in spheroid and
monolayer cultures of rat hepatocytes.
A. ICHIHARA [Vol. 86, 712intracellular structure such as integrin and cytoskele-
ton was limited to allow me investigate this area. This
challenge was also close to my retirement from the
University.
At that time, Dr. Keiji Tanaka started working
in my laboratory as a research assistant and was
interested in protein turnover, because he graduated
from the Department of Nutrition at Tokushima
University. He was particularly interested in energy
required for intracellular protein degradation. From
my side, I was curious about the possible involvement
of BCAA in protein turnover as mentioned above.
Accordingly, we started to look for possible proteases
involved in protein degradation. The prevailing
concept at that time was that protein degradation
served mainly to dispose old proteins and that this
process involved proteases such as trypsin and
chymotrypsin, though there was little interest in
intracellular proteases. Scientists also doubted that
protein degradation is an active process that requires
energy. Quite the opposite, it turned out to be a very
active process involving a large and complex pro-
tease. Dr. Tanaka was successful in separating the
protease and named it the proteasome. It contained
28 subunits with a relative molecular mass of about
750,000. Then, he identiﬁed the structure of each
subunit by cDNA cloning and showed that these
subunits are not-identical (though signiﬁcantly sim-
ilar) in amino acid sequence and that they form 4
discs (i.e., ,OO, ring) with 7 subunits each as shown
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Fig. 3. Schematic diagram of the 26S proteasome complex. Left panel: Gross structure (averaged image) of the 20S proteasome based on
electron micrography. Photograph kindly provided by W. Baumeister. The , and O rings of the 20S proteasome are indicated. Yellow
scissors image the location of two sets of active sites, which are present in the cavity of two O-rings. Right panel: Schematic drawing of
the subunit structure. The 20S proteasome consists of two outer , rings and two inner O rings, which are made up of seven structurally
similar , and O subunits, respectively; the rings form an ,1–7O1–7O1–7,1–7 structure. The O1, O2, and O5 subunits are associated with the
caspase-like, trypsin-like, and chymotrypsin-like activities, respectively. The 19S regulatory particle (RP) caps on both ends of the
central 20S proteasomal core. The 19S RP comprises many diﬀerent subunits that can be subclassiﬁed into two groups: Regulatory
particle of triple-ATPase (Rpt) subunits and Regulatory particle of non-ATPase (Rpn) subunits.
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Fig. 4. Proposed relation between BCAA, HGF and protea-
somes. For details, see text.
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some) is attached to the regulatory part on each side
to make the larger complex (designated 26S protea-
some). In 1996, Dr. Tanaka moved to the Frontier
Science Laboratory at the Tokyo Metropolitan
Institute of Medical Science. His work had estab-
lished the role of proteasomes and they were known
at that stage to be the main regulators of a multitude
of cell activities. Further work showed that the
proteasome degrades short-live proteins in the cells,
such as receptors of growth factors, factors for cell
cycle, transcription factors and MHC class I anti-
gens.27) I should mention here that I did not cite
much work of Drs. Nakamura and Tanaka on HGF
and proteasomes, respectively, because most of that
work was theirs.21),22),27)
I retired from Tokushima University in 1994
and that was the end of my research work. I hope
that I summarized my 40 years of work adequately. I
know it is not simple or easy, because I did not have a
deep philosophy in my work. The ﬁrst part of my
research work followed the advice of my mentor; i.e.,
characterization of metabolic pathways of amino
acids, such as cysteine, serine and lysine. The work
on BCAA was purely my own. In general, amino
acids are usually used for gluconeogenesis and hence
I usually used the rat liver. BCAA degradation is
unique compared with the degradation of other amino
acids, because they are degraded in extrahepatic
tissues. They may become a signal via mTOR for
protein turnover as suggested in Fig. 4.28) HGF also
has a potent insulin action and HGF receptor (cMet)
is degraded (regulated) by proteasomes. Proteasomes
also regulate BCAA signals. Each of these research
projects was conducted separately and independently,
but I can ﬁrmly say that the entire work conducted
over 40 years can be viewed as pieces of a jigsaw
puzzle put together to form one big picture. Looking
back now I can say that I had a happy and enjoyable
40-year research life. Most importantly, I was
surrounded by many distinguished and kind senior
and junior researchers and they were the most helpful
in my life. I want to thank each one of them for the
collaborative and enjoyable work we did together.
Finally, I want to mention the contribution of
my dear wife Elizabeth to life science in Japan. She
has contributed enormously by editing a number
of Japanese papers (including mine) published in
English. Elizabeth was born in Cambridge, grad-
uated from Newnham College and obtained her PhD
in marine biology. She joined Professor Greenberg’s
laboratory in Berkeley and then moved to Osaka
with me in 1957. It was just the time during which
Japanese life science research had started to match
that in other countries and many excellent papers
were being published. As most of you know and
suﬀer, all Japanese scientists found it diﬃcult at that
time to write papers in English, in addition to the
lack of good quality science translators. Elizabeth
was the most proper person for that task. It was
natural that she found a lot of interest in her editing
skills by the Japanese life scientists, and she did help
them edit their papers to as many as 400 per year.
She realized her importance in this work and valued
it much more than her research work. Based on this
realization, she gave up work in research and devoted
her time to editing. It is my estimate that she edited
as many as 10,000 manuscripts written by Japanese
scientists during her carrier. In 1982, Professor
Tamio Yamakawa suggested the publication of a
book entitled “How to write science papers in
English”. The book was published by Kyoritsu
Shuppan and has become one of the best sellers
published by that company; over 31,000 copies have
been sold and it is still being reprinted. Elizabeth’s
motto in science writing was “simple, accurate and
clear”, and she hated words like “may be” or “suggest”.
Sadly, Elizabeth died in 2009. Her brother, David
and I wrote an obituary in Newnham College
Roll Letter in 2009 (800th anniversary of the Cam-
bridge University, p. 214). Also, Dr. Yasuhiro
Anraku kindly wrote an obituary in Seikagaku
(2009;81:823–825).
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Akira Ichihara was born in 1928 at Osaka and graduated the Medical School of
Osaka University in 1952 and then entered Graduate School of the Institute of Microbial
Diseases. His ﬁrst work was to characterize cysteine desulfhydratase of bacteria and rat
liver. From 1954 he spent three years in USA as a postdoctoral fellow, and studied serine
biosynthesis in rat liver. In 1957 he came back to Osaka University and characterized
transaminase of branched chain amino acids in animal tissues. In 1965 he was appointed
as Professor of Enzyme Pathology, Tokushima University. He was interested in
diﬀerentiated cultured liver cells using primary cultures of rat hepatocytes. Markers of
diﬀerentiation were amino acid metabolizing enzymes and their genes expression by
addition of various hormones. He characterized growth factor of these hepatocytes and
named as Hepatocyte Growth Factor (HGF). Final part of his research life till his retirement was to characterize an
energy-dependent protein degrading enzyme termed as the proteasome. He retired academic life from a chairman of
Enzyme Research Center of the Tokushima University (1994). Therefore, his research as a whole was for
characterization of nitrogen metabolism in animals. He served as Presidents of Jpn. Soc. Biochem. (1990) and Jpn.
Soc. Cell Biol. (1992). He was an honorary member of Jpn. Soc. Biochem. and Am. Soc. Mol. Biol. Biochem. He was
awarded Academic prizes for the Princess Takamatsu Cancer Research and the Uehara Foundation.
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